Cognition Therapeutics Inc
NASDAQ:CGTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
US |
|
Wellnex Life Ltd
ASX:WNX
|
AU |
|
Computer Engineering & Consulting Ltd
TSE:9692
|
JP |
|
Archrock Inc
NYSE:AROC
|
US |
|
T
|
Thor Medical ASA
OSE:TRMED
|
NO |
|
H
|
Hanil Cement Co Ltd
KRX:300720
|
KR |
|
A
|
Atlas Global Brands Inc
CNSX:ATL
|
CA |
|
Graphic Packaging Holding Co
NYSE:GPK
|
US |
|
I
|
InFocus Group Holdings Ltd
ASX:IFG
|
AU |
Cognition Therapeutics Inc
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.
Strategy shift: Cognition is now prioritizing zervimesine for dementia with Lewy body, or DLB, psychosis after reviewing Phase II data and feedback from regulators.
DLB data: Management highlighted an 86% slowing of progression on the NPI-12 neuropsychiatric symptoms measure, with the strongest effects seen on hallucinations and delusions.
FDA path: The company said the FDA directed it to the Division of Psychiatry to define a registrational path, and Cognition has already filed a meeting request.
Alzheimer's still active: Cognition remains committed to Alzheimer's disease, but DLB psychosis is now the first priority while it waits for START trial results in 2027.
Cash runway: The company ended 2025 with about $37 million in cash and said it has enough funding to operate through the second quarter of 2027.
